|
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not
intended to be used as a source of information on on healthcare or medicines.
The web pages are not kept up to date and are for demonstration purposes only.
For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines
or the package leaflet of your medicine. For up-to-date information on other
healthcare topics, please consult the relevant reliable sources or an healthcare
expert, such as a physician etc.
|
BACK TO LIST |
Laboratory Report
|
|
|
|||||||||||||||||||||||||
Hematology
| Test | 31-JAN-2025 | Reference Range | Unit |
|---|---|---|---|
| Leukocytes [#/volume] in Blood by Automated count | 9.4 | 3.6 - 10.5 | 10*3/uL |
| Erythrocytes [#/volume] in Blood by Automated count | 5.2 | 4.3 - 6.1 | 10*6/uL |
| Hemoglobin [Mass/volume] in Blood | 15.4 | 13.5 - 17.5 | g/dL |
| Hematocrit [Volume Fraction] of Blood by Automated count | 49.6 | 38 - 50 | % |
| MCV [Entitic volume] by Automated count | 91.5 | 76 - 98 | fL |
| MCH [Entitic mass] by Automated count | 30.4 | 27 - 33 | pg |
| MCHC [Mass/volume] by Automated count | 32.6 | 31 - 37 | g/dL |
| Erythrocyte distribution width [Ratio] by Automated count | 13.7 | 11.6 - 16.5 | % |
| Platelets [#/volume] in Blood by Automated count | 419.4 H | 155 - 415 | 10*3/uL |
Chemistry
| Test | 31-JAN-2025 | Reference Range | Unit |
|---|---|---|---|
| Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 611.5 | 300 - 900 | pg/mL |
| Glucose [Mass/volume] in Serum or Plasma | 193.3 H | 70 - 140 | mg/dL |
| Urea nitrogen [Mass/volume] in Serum or Plasma | 7.1 | 7 - 50 | mg/dL |
| Creatinine [Mass/volume] in Serum or Plasma | 0.8 L | 0.9 - 1.3 | mg/dL |
| Calcium [Mass/volume] in Serum or Plasma | 9.0 | 8.5 - 10.5 | mg/dL |
| Sodium [Moles/volume] in Serum or Plasma | 140.7 | 135 - 145 | mmol/L |
| Potassium [Moles/volume] in Serum or Plasma | 4.5 | 3.5 - 5.1 | mmol/L |
| Chloride [Moles/volume] in Serum or Plasma | 106.3 | 98 - 108 | mmol/L |
| Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25.6 | 22 - 32 | mmol/L |
| Protein [Mass/volume] in Serum or Plasma | 6.1 | 6 - 8.3 | g/dL |
| Albumin [Mass/volume] in Serum or Plasma | 5.0 | 3.5 - 5.5 | g/dL |
| Bilirubin.total [Mass/volume] in Serum or Plasma | 1.2 | 0.3 - 1.2 | mg/dL |
| Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 85.1 | 40 - 117 | U/L |
| Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38.5 | 10 - 66 | U/L |
| Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19.3 | 10 - 40 | U/L |
| Magnesium [Mass/volume] in Serum or Plasma | 1.8 | 1.6 - 2.6 | mg/dL |
| Cholesterol [Mass/volume] in Serum or Plasma | 252.0 H | 0 - 200 | mg/dL |
| Triglyceride [Mass/volume] in Serum or Plasma | 308.3 H | 0 - 199 | mg/dL |
| Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay | 150.4 H | 0 - 130 | mg/dL |
| Cholesterol in HDL [Mass/volume] in Serum or Plasma | 39.9 L | 40 - 100 | mg/dL |
| Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | 4.5 - 6.4 | % |
| Troponin I.cardiac [Mass/volume] in Serum or Plasma by High sensitivity method | 0.0 | 0 - 19.9 | pg/mL |
| Ferritin [Mass/volume] in Serum or Plasma | 117.8 | 30 - 300 | ug/L |
| Iron [Mass/volume] in Serum or Plasma | 71.8 | 65 - 300 | ug/dL |
| Iron binding capacity [Mass/volume] in Serum or Plasma | 316.0 | 250 - 450 | ug/dL |
| Iron saturation [Mass Fraction] in Serum or Plasma | 39.0 | 15 - 45 | % |
Annotation
| Conclusion and Recommendations based on this report and previous findings known to us |
|---|
| Most parameters are within normal limits. Notable findings include mild thrombocytosis, hyperglycemia (with normal HbA1c suggesting acute elevation), and dyslipidemia (elevated total cholesterol, LDL, triglycerides, and low HDL), which increase cardiovascular risk. Creatinine is slightly below the reference range but not clinically significant. Cardiac markers (NT-proBNP, troponin) are within expected ranges for age. Recommend clinical correlation for hyperglycemia and lipid abnormalities, and consider follow-up for cardiovascular risk management. |